GB2597377A - Systems and methods for modulating CRISPR activity - Google Patents
Systems and methods for modulating CRISPR activity Download PDFInfo
- Publication number
- GB2597377A GB2597377A GB2110534.1A GB202110534A GB2597377A GB 2597377 A GB2597377 A GB 2597377A GB 202110534 A GB202110534 A GB 202110534A GB 2597377 A GB2597377 A GB 2597377A
- Authority
- GB
- United Kingdom
- Prior art keywords
- polynucleotide
- nucleotide
- cleavable linker
- guide sequence
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091033409 CRISPR Proteins 0.000 title claims abstract 54
- 238000010354 CRISPR gene editing Methods 0.000 title claims abstract 23
- 230000000694 effects Effects 0.000 title claims abstract 16
- 238000000034 method Methods 0.000 title claims 74
- 108091033319 polynucleotide Proteins 0.000 claims abstract 187
- 102000040430 polynucleotide Human genes 0.000 claims abstract 187
- 239000002157 polynucleotide Substances 0.000 claims abstract 187
- 230000004048 modification Effects 0.000 claims abstract 23
- 238000012986 modification Methods 0.000 claims abstract 23
- 239000002773 nucleotide Substances 0.000 claims 83
- 125000003729 nucleotide group Chemical group 0.000 claims 83
- 102000039446 nucleic acids Human genes 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 21
- 150000007523 nucleic acids Chemical class 0.000 claims 21
- 238000003776 cleavage reaction Methods 0.000 claims 12
- 230000007017 scission Effects 0.000 claims 12
- -1 a!koxyalkyl Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 108091034117 Oligonucleotide Proteins 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- VHFVDEXSJFKLDW-UHFFFAOYSA-N OS(S(O)(=O)=O)(S(O)(=O)=O)=O Chemical compound OS(S(O)(=O)=O)(S(O)(=O)=O)=O VHFVDEXSJFKLDW-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004429 atom Chemical group 0.000 claims 4
- 230000000536 complexating effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 3
- 125000005631 S-sulfonamido group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims 3
- 229960000956 coumarin Drugs 0.000 claims 3
- 235000001671 coumarin Nutrition 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000003107 substituted aryl group Chemical group 0.000 claims 3
- POXIZPBFFUKMEQ-UHFFFAOYSA-N 2-cyanoethenylideneazanide Chemical group [N-]=C=[C+]C#N POXIZPBFFUKMEQ-UHFFFAOYSA-N 0.000 claims 2
- 108091028113 Trans-activating crRNA Proteins 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000002680 canonical nucleotide group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 150000008300 phosphoramidites Chemical class 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 230000033077 cellular process Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 1
- 239000012636 effector Substances 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797122P | 2019-01-25 | 2019-01-25 | |
| US201962876177P | 2019-07-19 | 2019-07-19 | |
| US201962939553P | 2019-11-22 | 2019-11-22 | |
| PCT/US2020/015127 WO2020154714A2 (en) | 2019-01-25 | 2020-01-25 | Systems and methods for modulating crispr activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB202110534D0 GB202110534D0 (en) | 2021-09-08 |
| GB2597377A true GB2597377A (en) | 2022-01-26 |
Family
ID=71735803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB2110534.1A Withdrawn GB2597377A (en) | 2019-01-25 | 2020-01-25 | Systems and methods for modulating CRISPR activity |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11884918B2 (https=) |
| EP (1) | EP3914714A4 (https=) |
| JP (1) | JP2022523055A (https=) |
| KR (1) | KR20210123309A (https=) |
| CN (1) | CN113874503A (https=) |
| AU (1) | AU2020210884A1 (https=) |
| CA (1) | CA3127486A1 (https=) |
| GB (1) | GB2597377A (https=) |
| WO (1) | WO2020154714A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210045360A (ko) | 2018-05-16 | 2021-04-26 | 신테고 코포레이션 | 가이드 rna 설계 및 사용을 위한 방법 및 시스템 |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US20220411790A1 (en) * | 2019-10-25 | 2022-12-29 | The Johns Hopkins University | A crispr-cas9 platform with an intrinsic off-switch and enhanced specificity |
| US20240200059A1 (en) * | 2021-04-09 | 2024-06-20 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
| CN114410752B (zh) * | 2022-01-24 | 2024-06-25 | 华南师范大学 | 一种基于光控的CRISPR-Cas核酸检测试剂盒及检测方法 |
| US20260103702A1 (en) * | 2022-09-30 | 2026-04-16 | Board Of Trustees Of Southern Illinois University | Compositions and methods for crispr modulation |
| WO2024215715A2 (en) * | 2023-04-11 | 2024-10-17 | President And Fellows Of Harvard College | Chemical ligation techniques |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140235508A1 (en) * | 2011-11-04 | 2014-08-21 | National University Corporation Saitama University | Nucleic acid linker |
| US20160206566A1 (en) * | 2014-10-31 | 2016-07-21 | President And Fellows Of Harvard College | Delivery of cas9 via arrdc1-mediated microvesicles (armms) |
| US20160215300A1 (en) * | 2015-01-28 | 2016-07-28 | Pioneer Hi-Bred International. Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
| US20160237439A1 (en) * | 2013-10-14 | 2016-08-18 | Stc.Unm | Modular rna regulators and methods |
| US20170114334A1 (en) * | 2014-06-25 | 2017-04-27 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US20090181858A1 (en) * | 2004-09-21 | 2009-07-16 | The Scripps Research Institute | Adding photoregulated amino acids to the genetic code |
| BRPI0617191A2 (pt) * | 2005-10-12 | 2011-07-19 | Scripps Research Inst | modificação pós-traducional de polipeptìdeos expressos em fagos |
| US8158595B2 (en) | 2006-11-09 | 2012-04-17 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
| US9371348B2 (en) | 2006-11-27 | 2016-06-21 | The Trustees Of The University Of Pennsylvania | Photocleavable oligonucleotide and uses thereof |
| US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| US7923562B2 (en) | 2008-06-16 | 2011-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | Photocleavable linker methods and compositions |
| JP2011525180A (ja) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| BRPI1012036A2 (pt) | 2009-05-27 | 2017-10-10 | Selecta Biosciences Inc | nanocarreadores que possuem componentes com diferentes taxas de liberação |
| EA201290497A1 (ru) | 2009-12-15 | 2013-01-30 | Байнд Байосайенсиз, Инк. | Терапевтические полимерные наночастицы, включающие кортикостероиды, и способы получения таковых |
| WO2011107747A2 (en) * | 2010-03-05 | 2011-09-09 | Medical Research Council | Genetically encoded photocontrol |
| US20130037977A1 (en) | 2010-04-08 | 2013-02-14 | Paul A. Burke | Preparation of Lipid Nanoparticles |
| US20120171229A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| US9228207B2 (en) * | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| WO2016022866A1 (en) | 2014-08-07 | 2016-02-11 | Agilent Technologies, Inc. | Cis-blocked guide rna |
| WO2016094874A1 (en) * | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| JP2018515142A (ja) * | 2015-05-15 | 2018-06-14 | ダーマコン，インコーポレイテッド． | Ｃａｓ９介在遺伝子編集用の合成シングルガイドｒｎａ |
| EP3353309A4 (en) * | 2015-09-25 | 2019-04-10 | Tarveda Therapeutics, Inc. | COMPOSITIONS AND METHOD FOR GENERIC EDITING |
| CN109072224B (zh) * | 2016-01-30 | 2022-07-15 | 株式会社博纳克 | 人工单导rna及其用途 |
| US20200291369A1 (en) | 2016-03-11 | 2020-09-17 | Erasmus University Medical Center Rotterdam | Improved CRISPR-Cas9 Genome Editing Tool |
| EP3219799A1 (en) * | 2016-03-17 | 2017-09-20 | IMBA-Institut für Molekulare Biotechnologie GmbH | Conditional crispr sgrna expression |
| CN109415729B (zh) | 2016-04-21 | 2022-12-09 | 生命技术公司 | 具有降低毒性的基因编辑试剂 |
| WO2017217768A1 (ko) * | 2016-06-15 | 2017-12-21 | 주식회사 툴젠 | 온타겟 및 오프타겟의 다중 타겟 시스템을 이용하는, 표적 특이적 유전자 가위 스크리닝 방법 및 이의 용도 |
| EP3638789A4 (en) * | 2017-06-12 | 2021-03-10 | California Institute of Technology | CONDITIONAL GUIDE RNAS |
-
2020
- 2020-01-25 CN CN202080024105.4A patent/CN113874503A/zh active Pending
- 2020-01-25 GB GB2110534.1A patent/GB2597377A/en not_active Withdrawn
- 2020-01-25 KR KR1020217023538A patent/KR20210123309A/ko not_active Abandoned
- 2020-01-25 JP JP2021543277A patent/JP2022523055A/ja active Pending
- 2020-01-25 AU AU2020210884A patent/AU2020210884A1/en not_active Abandoned
- 2020-01-25 WO PCT/US2020/015127 patent/WO2020154714A2/en not_active Ceased
- 2020-01-25 CA CA3127486A patent/CA3127486A1/en active Pending
- 2020-01-25 EP EP20744712.9A patent/EP3914714A4/en active Pending
-
2021
- 2021-07-23 US US17/384,328 patent/US11884918B2/en active Active
-
2023
- 2023-12-07 US US18/532,892 patent/US20240209356A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140235508A1 (en) * | 2011-11-04 | 2014-08-21 | National University Corporation Saitama University | Nucleic acid linker |
| US20160237439A1 (en) * | 2013-10-14 | 2016-08-18 | Stc.Unm | Modular rna regulators and methods |
| US20170114334A1 (en) * | 2014-06-25 | 2017-04-27 | Caribou Biosciences, Inc. | RNA Modification to Engineer Cas9 Activity |
| US20160206566A1 (en) * | 2014-10-31 | 2016-07-21 | President And Fellows Of Harvard College | Delivery of cas9 via arrdc1-mediated microvesicles (armms) |
| US20160215300A1 (en) * | 2015-01-28 | 2016-07-28 | Pioneer Hi-Bred International. Inc. | Crispr hybrid dna/rna polynucleotides and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| (JAIN, P. et al) Development Of Light-Activated CRISPR Using Guide RNAs With Photocleavable Protectors. Angewandte International Edition Chemie. 2016, Vol, 55, pages 12440-12444; Figures 1a, 3-4; Figures 1, 3-4, S11 legend; Supporting Figure S2; page 12440, column 2, third paragraph; ; page 12441, f * |
| (LIU, Q.) Synthesis Of Photo- And Chemical-Activated Nucleosides And Unnatural Amino Acids. Dissertation. North Carolina State University. 2014, pages 1-296; Schemes 4. 1 4.6; Scheme 4.6 legend; abstract; page 17, second paragraph; page 25, first paragraph; page 120, second paragraph; page 125, seco * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3127486A1 (en) | 2020-07-30 |
| US20240209356A1 (en) | 2024-06-27 |
| JP2022523055A (ja) | 2022-04-21 |
| EP3914714A2 (en) | 2021-12-01 |
| CN113874503A (zh) | 2021-12-31 |
| KR20210123309A (ko) | 2021-10-13 |
| WO2020154714A2 (en) | 2020-07-30 |
| US11884918B2 (en) | 2024-01-30 |
| AU2020210884A1 (en) | 2021-08-12 |
| EP3914714A4 (en) | 2024-04-10 |
| US20220073912A1 (en) | 2022-03-10 |
| GB202110534D0 (en) | 2021-09-08 |
| WO2020154714A3 (en) | 2020-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2597377A (en) | Systems and methods for modulating CRISPR activity | |
| JP7833596B2 (ja) | ３’－ヒドロキシブロッキング基を有するヌクレオシドおよびヌクレオチド、ならびにそれらのポリヌクレオチドシーケンシング方法における使用 | |
| CN115867560B (zh) | 具有3’缩醛封端基团的核苷与核苷酸 | |
| Semenyuk et al. | Synthesis of RNA using 2 ‘-O-DTM protection | |
| McGall et al. | The efficiency of light-directed synthesis of DNA arrays on glass substrates | |
| JP2019523242A (ja) | Ｒｎａ機能をモジュレートするための化合物および方法 | |
| Praseuth et al. | Double helices with parallel strands are formed by nuclease-resistant oligo-[α]-deoxynucleotides and oligo-[α]-deoxynucleotides covalently linked to an intercalating agent with complementary oligo-[β]-deoxynucleotides | |
| JPH07502654A (ja) | 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｈｉｖプローブ | |
| JPH05507000A (ja) | ヌクレオシド−５’−ｏ−（１−チオトリホスフェート）を用いる改良された核酸シーケンス分析 | |
| FR2824335A1 (fr) | Procede de marquage et de fragmentation d'adn | |
| Praseuth et al. | Sequence-targeted photosensitized reactions in nucleic acids by oligo-. alpha.-deoxynucleotides and oligo-. beta.-deoxynucleotides covalently linked to proflavin | |
| US20030143555A1 (en) | Method for labeling and fragmenting DNA | |
| Khodyreva et al. | Photoaffinity labeling technique for studying DNA replication and DNA repair | |
| CN106188197A (zh) | 光可断裂的荧光标记化合物及用途 | |
| CA3182311A1 (en) | Methods and compositions for nucleic acid sequencing | |
| CN116685694A (zh) | 用于检测核苷酸修饰的方法 | |
| CN107250147A (zh) | 通用甲基化分析方法 | |
| Guiney et al. | Syntheses of highly functionalised 6-substituted pteridines | |
| JP4712814B2 (ja) | 特定の塩基配列の標的核酸類を検出する方法、及び検出のための核酸類セット | |
| Tsai et al. | Rhodium‐Catalyzed Domino Hydroformylation/Double‐Cyclization Reaction of Arylacetylenecarboxamides: Diastereoselectivity Studies and Application in the Synthesis of 1‐Azabicyclo [xy 0] alkanes | |
| An et al. | 5-Enolpyruvylshikimate 3-phosphate synthase: chemical synthesis of the tetrahedral intermediate and assignment of the stereochemical course of the enzymatic reaction | |
| Saran et al. | A versatile photocleavable bifunctional linker for facile synthesis of substrate− DNA conjugates for the selection of nucleic acid catalysts | |
| CN117758374A (zh) | 一种On-DNAα-羟基烯烃类先导化合物及其合成方法 | |
| Summerton | Sequence-specific crosslinking agents for nucleic acids: design and functional group testing | |
| Sun et al. | Discovery of Photoexcited 2‐Chloro‐3, 5‐Dinitrobenzoic Acid as a Chemical Deprenylase of i6A RNA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |